0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Improved Prospects for Long-term Survival in Adults With Acute Myelogenous Leukemia

Michael J. Keating, MB, BS; Kenneth B. McCredie, MB, BS; Gerald P. Bodey, MD; Terry L. Smith; Edmund Gehan, PhD; Emil J Freireich, MD
JAMA. 1982;248(19):2481-2486. doi:10.1001/jama.1982.03330190045029.
Text Size: A A A
Published online

An improved complete remission rate in acute myelogenous leukemia (AML) has been noted since cytarabine and anthracyclines were introduced into clinical practice. Forty-one (9%) of 457 patients with AML treated between 1965 and 1976 have survived more than five years. The proportion of five-year survivors for patients treated between 1973 and 1976, 1970 and 1972, and 1965 and 1969 were 11.8%, 8.8%, and 1.8%, respectively. The major factor influencing five-year survival was whether or not patients were treated with cytarabine alone or combined with an anthracycline. Thirty-six (17%) of the 207 complete responders remained in continuous complete remission for more than five years. Twenty-four of the 36 patients who are in remission for more than five years have not been receiving chemotherapy for more than five years and are considered potentially cured.

(JAMA 1982;248:2481-2486)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();